BiomX Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BiomX Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of natural and engineered bacteriophage (phage) therapies designed to target and eradicate specific harmful bacteria associated with chronic diseases. Its core product pipeline includes phage cocktails and personalized phage treatments targeting diseases such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), colorectal cancer (CRC), diabetic foot osteomyelitis (DFO), cystic fibrosis (CF), and acne-prone skin conditions. Key product candidates under development include BX001 for acne-prone skin, BX002 for IBD, BX003 targeting Klebsiella pneumoniae strains, BX211 for diabetic foot osteomyelitis, and BX004, a fixed multi-phage cocktail aimed at treating chronic pulmonary infections caused by Pseudomonas aeruginosa in CF and non-CF bronchiectasis patients. BiomX customizes phage cocktails based on bacterial targets, utilizing both natural and engineered phage technologies. The company operates globally and is headquartered in Ness Ziona, Israel, with a foundation year of 2015. In recent major developments, BiomX completed the acquisition of Adaptive Phage Therapeutics (APT) in early 2024, creating an expanded clinical pipeline and reinforcing its position as a leading phage therapy company. The merger added mid-clinical-stage programs including BX211 and expanded BiomX’s technological capabilities. Concurrent with the acquisition, BiomX raised $50 million in a private placement led by institutional investors including Deerfield Management Company and the AMR Action Fund to finance Phase 2b clinical trials of BX004 and other programs. The company also secured additional funding from the U.S. Defense Health Agency to advance the diabetic foot osteomyelitis program. BX004 received FDA orphan drug designation and Fast Track status, with positive Phase 1b/2a trial results announced in late 2023 showing improvement in pulmonary function in cystic fibrosis patients. BiomX expects key clinical data readouts for BX211 and BX004 in 2025, aiming to advance these leading candidates toward regulatory approvals and commercialization. BiomX primarily serves the biopharmaceutical and healthcare markets with its innovative microbiome-based phage therapies. It targets specific patient populations suffering from chronic and difficult-to-treat bacterial infections and inflammatory conditions. The company integrates discovery, development, and clinical evaluation of its phage therapies worldwide, focusing on diseases with significant unmet medical needs. BiomX maintains a focus on research-driven, personalized medicine strategies in its biopharmaceutical segment, employing proprietary phage technology platforms to deliver targeted bacterial eradication while preserving beneficial microbiota. The company also offers a diversified pipeline encompassing skin health and respiratory disease specialties alongside gastrointestinal and wound infection treatments. This strategic expansion via merger, funding, and advanced clinical development activities positions BiomX at the forefront of the emerging phage therapy sector within biotechnology and medical research. The combination of proprietary natural and engineered phage technology platforms with late-stage clinical assets underlines BiomX’s innovative approach to addressing bacterial infections that are resistant or inadequately managed by conventional antibiotics. Overall, BiomX continues to grow as a globally operational company headquartered in Israel, developing next-generation bacteriophage therapeutics for chronic disease indications associated with microbial dysbiosis and infection.
Company News
BiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response Workflows
BiomX Inc. to Become Tessera Defense and Homeland Security Inc.
BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site
BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous Systems
BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms
BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe
BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities
BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities
BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement
BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement
BiomX Inc. (PHGE) Shareholder/Analyst Call Prepared Remarks Transcript
BiomX: Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026
BiomX Provides Update on Defense Technology Portfolio and Growth Strategy
BiomX Announces NYSE American Acceptance of Plan to Regain Compliance
BiomX: Zorronet's AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global Events
Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit
Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence
BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations
BiomX's Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand